For Referring Healthcare Providers

Manage your referrals and track patients receiving Bristol Myers Squibb CAR T cell therapy through the Referral Dashboard.

The decision to refer a patient, and the selection of a particular certified CAR T cell therapy treatment center, is made solely by the referring provider and the patient. It is the referring provider’s responsibility to follow all legal and institution requirements for such referrals. Only a certified CAR T cell therapy treatment center can decide if CAR T cell therapy is the appropriate treatment choice for a patient.

Your Role in the CAR T Cell Therapy Treatment Journey

As a referring healthcare provider, you play an integral role in ensuring your patients receive the treatment they need as soon as they’re ready.

Cell Therapy 360® resources assist you and your patients throughout the CAR T cell therapy referral process. Tools provided will help with:

Step 1 Eligibility Identification

Determining your patient’s potential CAR T cell therapy eligibility can inform your decision in getting them to a consultation.

Step 2 Patient Referral

Once you’ve identified a potential CAR T cell therapy patient, get help with:

  • Finding certified Bristol Myers Squibb CAR T cell therapy treatment centers
  • Checking your patient’s CAR T cell therapy benefits coverage
  • Scheduling a CAR T cell therapy consultation with your patient's treatment center of choice

Need help? Click here for a listing of nationwide resources to help your patient during their CAR T cell therapy journey.

Step 3 Manufacturing

If the certified treatment center determines CAR T cell therapy treatment is right for your patient, there are 4 steps that will occur:

  1. Leukapheresis: Your patients’ T cells are collected.
  2. Manufacturing: Your patients’ T cells are safely transported to a specialized manufacturing site. The cells are engineered and expanded to the appropriate cell count.
  3. A one-time treatment: Patients are given a one-time treatment with CAR T cells after receiving low doses of chemotherapy to prepare their bodies.
  4. Post-infusion monitoring period: During the initial post-infusion monitoring period (at least 4 weeks), patients are monitored by the certified treatment center for any possible side effects.

Step 4 Follow-up

After the infusion and the initial post-infusion monitoring period (at least 4 weeks), your patient may return to you and your team for ongoing monitoring, including regular care appointments.

Your Referral Dashboard can help track your patients who receive a Bristol Myers Squibb CAR T cell therapy

The decision to refer a patient, and the selection of a particular certified CAR T cell therapy treatment center, is made solely by the referring provider and the patient. It is the referring provider’s responsibility to follow all legal and institution requirements for such referrals. Only a certified CAR T cell therapy treatment center can decide if CAR T cell therapy is the appropriate treatment choice for a patient.

CAR=chimeric antigen receptor.